Advertisement

[Corrections] Correction to Lancet Oncol 2024; 25: 317–25

March, 03, 2024 | Select Oncology Journal Articles

Palmieri C, Linden H, Birrell SN, et al. Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial. Lancet Oncol 2024; 25: 317–25—In this Article, the first sentence of the Introduction should read as follows: “Pre-clinical models of oestrogen receptor (ER)-positive, HER2-negative breast cancer have established that the androgen receptor (AR) functions as a tumour suppressor and activation of this receptor strongly suppresses the growth of AR-positive, ER-positive breast cancer…”.

For Additional News from OncWeekly – Your Front Row Seat To The Future of Cancer Care –

Advertisement

LATEST

Advertisement

Sign up for our emails

Trusted insights straight to your inbox and get the latest updates from OncWeekly

Privacy Policy